非核苷类逆转录酶抑制剂可在潜伏期逆转后减少潜伏感染的静息CD4 T细胞产生HIV-1。
Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4 T Cells following Latency Reversal.
作者信息
Zerbato Jennifer M, Tachedjian Gilda, Sluis-Cremer Nicolas
机构信息
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia.
出版信息
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01736-16. Print 2017 Mar.
Abstract
Therapeutic strategies that target the latent HIV-1 reservoir in resting CD4 T cells of infected individuals are always administered in the presence of combination antiretroviral therapy. Using a primary cell of HIV-1 latency, we evaluated whether different antiviral drug classes affected latency reversal (as assessed by extracellular virus production) by anti-CD3/CD28 monoclonal antibodies or bryostatin 1. We found that the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine significantly decreased HIV-1 production, by ≥1 log.
摘要
针对受感染个体静息CD4 T细胞中潜伏的HIV-1储存库的治疗策略总是在联合抗逆转录病毒疗法的情况下进行。我们使用HIV-1潜伏的原代细胞，评估了不同类别的抗病毒药物是否会影响抗CD3/CD28单克隆抗体或苔藓抑素1介导的潜伏逆转（通过细胞外病毒产生来评估）。我们发现，非核苷类逆转录酶抑制剂依非韦伦和利匹韦林可使HIV-1产生量显著降低≥1个对数。
相似文献
1
Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4 T Cells following Latency Reversal.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01736-16. Print 2017 Mar.
2
Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
J Virol. 2022 Feb 23;96(4):e0195321. doi: 10.1128/JVI.01953-21. Epub 2021 Dec 8.
3
CD32 expression is associated to T-cell activation and is not a marker of the HIV-1 reservoir.
Nat Commun. 2018 Jul 16;9(1):2739. doi: 10.1038/s41467-018-05157-w.
4
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.
5
The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
Sci Rep. 2017 May 24;7(1):2385. doi: 10.1038/s41598-017-02634-y.
6
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Virology. 2018 Jul;520:83-93. doi: 10.1016/j.virol.2018.05.006. Epub 2018 May 26.
7
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.
8
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
PLoS Pathog. 2017 Sep 21;13(9):e1006575. doi: 10.1371/journal.ppat.1006575. eCollection 2017 Sep.
9
The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models.
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00138-21.
10
Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
Antiviral Res. 2015 Nov;123:163-71. doi: 10.1016/j.antiviral.2015.09.014. Epub 2015 Sep 30.
引用本文的文献
1
Interplay between protease and reverse transcriptase dimerization in a model HIV-1 polyprotein.
Protein Sci. 2024 Jul;33(7):e5080. doi: 10.1002/pro.5080.
2
CARD8 Inflammasome Activation by HIV-1 Protease.
Methods Mol Biol. 2023;2641:67-79. doi: 10.1007/978-1-0716-3040-2_6.
3
Chemical inhibition of DPP9 sensitizes the CARD8 inflammasome in HIV-1-infected cells.
Nat Chem Biol. 2023 Apr;19(4):431-439. doi: 10.1038/s41589-022-01182-5. Epub 2022 Nov 10.
4
CROI 2022: summary of basic science research in HIV and SARS-CoV-2.
Top Antivir Med. 2022 Apr-May;30(2):419-425.
5
CARD8 is an inflammasome sensor for HIV-1 protease activity.
Science. 2021 Mar 19;371(6535). doi: 10.1126/science.abe1707. Epub 2021 Feb 4.
6
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Viruses. 2020 Apr 27;12(5):489. doi: 10.3390/v12050489.
7
NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal.
Retrovirology. 2019 Jun 26;16(1):17. doi: 10.1186/s12977-019-0479-9.
本文引用的文献
1
Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro.
J Virol. 2016 Aug 26;90(18):8059-73. doi: 10.1128/JVI.00553-16. Print 2016 Sep 15.
2
Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
Curr Opin HIV AIDS. 2016 Jul;11(4):394-401. doi: 10.1097/COH.0000000000000279.
3
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
J Antimicrob Chemother. 2015 May;70(5):1482-6. doi: 10.1093/jac/dku575. Epub 2015 Feb 3.
4
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma.
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):438-41. doi: 10.1097/QAI.0b013e31828e6163.
5
Efavirenz enhances HIV-1 gag processing at the plasma membrane through Gag-Pol dimerization.
J Virol. 2013 Mar;87(6):3348-60. doi: 10.1128/JVI.02306-12. Epub 2013 Jan 9.
6
HIV: Shock and kill.
Nature. 2012 Jul 25;487(7408):439-40. doi: 10.1038/487439a.
7
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.
Retrovirology. 2010 Oct 15;7:89. doi: 10.1186/1742-4690-7-89.
8
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.
9
A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load.
Nat Protoc. 2008;3(7):1240-8. doi: 10.1038/nprot.2008.108.
10
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.
Blood. 2007 Dec 15;110(13):4161-4. doi: 10.1182/blood-2007-06-097907. Epub 2007 Sep 19.
Zotero 插件